TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Investing.com

Eli Lilly Outlook Brightens With FDA Wins and Global Expansion in Manufacturing

Investing.com Logo Investing.com By Timothy Fries
Eli Lilly Outlook Brightens With FDA Wins and Global Expansion in Manufacturing

Eli Lilly reported strong Q3 2025 financial results with 54% revenue increase, raised full-year guidance, and achieved significant FDA approvals for key pharmaceutical products like Mounjaro and Zepbound.

Insights
MS   neutral

Mentioned as one of the analysts raising price target for Bloom Energy


LLY   positive

Reported 54% revenue increase, exceeded market expectations, raised full-year guidance, achieved key FDA approvals, expanded manufacturing facilities, and demonstrated strong performance in product portfolio